New reaction pathways of dopamine under oxidative stress conditions: Nonenzymatic iron-assisted conversion to norepinephrine and the neurotoxins 6-hydroxydopamine and 6,7-dihydroxytetrahydroisoquinoline

Chemical Research in Toxicology

Volumn 12, Issue 11, 1999, Pages 1090-1097

  Napolitano, Alessandra ^a   Pezzella, Alessandro ^a   Prota, Giuseppe ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; BUFFER; CHELATING AGENT; DIMETHYL SULFOXIDE; DOPAMINE; FERRIC ION; FERROUS ION; GLUTATHIONE; HYDROGEN PEROXIDE; IRON; MANGANESE; MANNITOL; NEUROTOXIN; NORADRENALIN; NORSALSOLINOL; OXIDOPAMINE; OXYGEN 18; PROTOCATECHUALDEHYDE; QUINONE DERIVATIVE; UNCLASSIFIED DRUG; ZINC ION;

ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PH; REACTION ANALYSIS;

BENZALDEHYDES; CATALASE; CATECHOLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE; IRON; ISOQUINOLINES; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; NOREPINEPHRINE; OXIDATION-REDUCTION; OXIDATIVE STRESS; OXIDOPAMINE; OXYGEN RADIOISOTOPES; SPECTROPHOTOMETRY, ULTRAVIOLET; SYMPATHOLYTICS;

LETHRINIDAE;

EID: 0032728623     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx990079p     Document Type: Article

References (49)

1. Olanow, C. W. (1990) Oxidation reaction in Parkinson's disease. Neurology 40, 32-37.
2. Fhan, S., and Cohen, G. (1992) The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann. Neurol. 32, 804-812.
3. Perry, T. L., Godin, D. A., and Hansen, S. (1982) Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci. Lett. 33, 305-310.
4. Riederer, P., Sofic, E., and Rausch, W. D. (1989) Transition metals, ferritin, glutathione and ascorbic acid in parkinaonian brain. J. Neurochem. 52, 512-520.
5. Dexter, D. T., Carter, C. J., Wells, F. R., Javoy-Agid, F., Agid, Y., Lees, A., Jenner, P., and Marsden, C. D. L. (1990) Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 52, 381-389.
6. Schapira, A. H. V., Cooper, J. M., Dexter, D., Clark, J. B., Jenner, P., and Marsden, C. D. (1990) Mitocondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54, 823-827.
7. Spina, M. B., and Cohen, G. (1989) Dopamine turnover and glutathione oxidation: implication for Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 86, 1398-1400.
8. Cohen, G. (1986) Monoamine oxidase, hydrogen peroxide and Parkinson's disease. In Advances in Neurology (Yahr, M. D., and Bergmann, K. J., Eds.) Vol. 45, pp 119-125, Raven Press, New York.
9. Sofic, E., Paulus, W., Jellinger, K. A., Riederer, P., and Youdim, M. B. H. (1991) Selective increase of iron in substantia nigra zona compacta of parkinsonian brain. J. Neurochem. 56, 978-982.
10. Youdim, M. B. H., Ben-Shachar, D., and Riederer, P. (1989) Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? Ada Neurol. Scand. 126, 47-54.
11. Adam, J. D., Jr., and Odunze, I. N. (1991) Oxygen free radicals and Parkinson's disease. Free Radical Biol. Med. 10, 161-169.
12. Tranzer, J. P., and Thoenen, H. (1968) An electron microscopic study of selective acute degeneration of sympathetic nerve terminals after administration of 6-hydroxydopamine. Experientia 24, 155-156.
13. Langston, J. W., Irwin, I., and Ricaurte, G. A. (1987) Neurotoxins, parkinsonism and Parkinson's disease. Pharmacol. Ther. 32, 19-49.
14. Seiden, L. S., and Vosmer, G. (1984) Formation of 6-hydroxydopamine in caudate nucleus of the rat brain after a single large dose of methylamphetamine. Pharmacol., Biochem. Behav. 21, 29-31.
15. Yoshida, M., Ogawa, M., Suzuki, K., and Nagatsu, T. (1993) Parkinsonism produced by tetrahydroisoquinoline (TIQ) or the analogues. Adv. Neurol, 60, 207-211.
16. Naoi, M., Dostert, P., Yoshida, M., and Nagatsu, T. (1993) N-Methylated tetrahydroisoquinolines as dopaminergic neurotoxins. Adv. Neurol. 60, 212-216.
17. Naoi, M., Maruyama, W., and Dostert, P. (1995) Dopamine-derived 6,7-dihyaroxy-1,2,3,4-tetrahydroisoquinolines: oxidation and neurotoxicity. Prog. Brain Res. 106, 227-239.
18. Garcia-Moreno, M., Rodriguez-Lopez, J. N., Martinez-Ortiz, F., Tudela, J., Varon, R., and Garcia-Canovas, F. (1991) Effect of pH on the oxidation pathway of dopamine catalysed by tyrosinase. Arch. Biochem. Biophys. 288, 427-434.
19. Slivka, A., and Cohen, G. (1985) Hydroxyl radical attack on dopamine. J. Biol. Chem. 29, 15466-15472.
20. 2. J. Med. Chem. 38, 917-922.
21. Pezzella, A., d'Ischia, M., Napolitano, A., Misuraca, G., and Prota, G. (1997) Iron-mediated generation of the neurotoxin 6-hydroxydopamine quinone by reaction of fatty acid hydroperoxides with dopamine: a possible contributory mechanism for neuronal degeneration in Parkinson's disease. J. Med. Chem. 42, 2011-2017.
22. Napolitano, A., Pezzella, A., and Prota, G. (1999) 6,7-Dihydroxy-1,2,3,4-tetrahydroisoquinoline formation by iron mediated dopamine oxidation: a novel route to endogenous neurotoxins under oxidative stress conditions. Tetrahedron Lett. 40, 2833-2836.
23. Wehrli, P. A., Pigott, F., Fischer, U., and Kaiser, A. (1972) Oxidationsprodukte von 6-Hydroxy-dopamin. (Oxidation products of 6-Hydroxydopamine). Helv. Chim. Acta 55, 3057-3061.
24. Whaley, W. M., and Govindachari, T. R. (1951) The Pictet-Spengler synthesis of TQ and related compounds. In Organic Reactions (Adams, R., Ed.) Vol. 6, pp 151-190, John Wiley & Sons, New York.
25. Tse, D. C. S., McCreery, R. L., and Adams, R. N. (1976) Potential oxidative pathways of brain catecholamines. J. Med. Chem. 19, 37-40.
26. Zhang, F., and Dryhurst, G. (1994) Effects of L-cysteine on the oxidation chemistry of dopamine: new reaction pathways of potential relevance to idiopathic Parkinson's disease. J. Med. Chem. 37, 1084-1098.
27. 13C in the α-or β-side chain positions, and their application for structural studies on melanins by solid-state NMR spectroscopy. Justus Liebigs Ann. Chem. 1994, 563-567.
28. Swan, G. A. (1974) Structure, chemistry and biosynthesis of the melanins. In Fortschritte der Chemie Organischer Naturstoffe (Hertz, W., Grisenbach, H., and Kirby, G. W., Eds.) Vol. 31, pp 521-582 Springer-Verlag, Wien, Germany.
29. Dorris, R. L., and Shore, P. A. (1971) Amine uptake and storage mechaniams in the corpus striatum of rat and rabbit. J. Pharmacol. Exp. Ther. 179, 15-19.
30. Linert, W., Herlinger, E., Jameson, R. F., Kienzl, E., Jellinger, K., and Youdim, M. B. H. (1996) Dopamine, 6-hydroxydopamine, iron, and dioxygen-their mutual interaction and possible implication in the development of Parkinson's disease. Biochim. Biophys. Acta 1316, 160-168.
31. Kienzl, E., Puchinger, L., Jellinger, K., Linert, W., Stachelberger, H., and Jameson, R. F. (1995) The role of transition metals in the pathogenesis of Parkinson's disease. J. Neurol. Sci. 134, 69-78.
32. Smythies, J., and Galzigna, L. (1998) The oxidative metabolism of catecholamines in the brain: a Review. Biochim. Biophys. Acta 1380, 159-162.
33. Rabinovic, A. D., and Hastings, T. G. (1998) Role of endogenous glutathione in the oxidation of dopamine. J. Neurochem. 71, 2071-2078.
34. Spencer, J. P., Jenner, P., Daniel, S. E., Lees, A. J., Marsden, D. C., and Halliwell, B. (1998) Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species. J. Neurochem. 71, 2112-2122.
35. Barbeau, A. (1984) Manganese and extrapyramidal disorders. Neurotoxicology 5, 13-36.
36. Sawaky, Y., and Foote, C. F. (1983) Mechanism of C-C cleavage of cyclic diketones with alkaline hydrogen peroxide. The acyclic mechanism and its application to the basic autoxidation of pyrogallol. J. Am. Chem. Soc. 105, 5035-5040.
37. Becker, K. B., and Grab, C. A. (1977) The formation of unsaturated groups by heterolytic fragmentation In The Chemistry of Double-Bonded Functional Groups (Patai, S., Ed.) Supplement A, pp 653-723, John Wiley & Sons, New York.
38. Graham, D. G., Tiffany, S. M., Bell, W. R., Jr., and Gutknecht, W. F. (1978) Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine and related compounds toward C1300 neuroblastoma cells in vitro. Mol. Pharmacol. 14, 644-653.
39. Blank, C. L., McCreery, R. L., Wightman, R. M., Chey, W., and Adams, R. N. (1976) Intracyclization rates of 6-hydroxydopamine and 6-aminodopamine analogs under physiological conditions. J. Med. Chem. 19, 178-180.
40. Peter, M. G. (1989) Chemical modification of biopolymers by quinone and quinone methides. Angew. Chem., Int. Ed. 28, 555-570.
41. Thompson, D. C., Thompson, J. A., Sugumaran, M., and Moldeus, P. (1993) Biological and toxicological consequences of quinone methide formation. Chem.-Biol. Interact. 86, 129-162.
42. Senoh, S., Creveling, C. R., Udenfriend, S., and Witkop B. (1959) Chemical, enzymatic and metabolic studies on the mechanism of oxidation of dopamine. J. Am. Chem. Soc. 81, 6236-6240.
43. Mlakar, A., Batna, A., Dudda, A., and Spiteller, G. (1996) Iron-(II) ions induced oxidation of ascorbic acid and glucose. Free Radical Res. 25, 525-539.
44. Niwa, T., Takeda, N., Yoshizumi, H., Tatematsu, A., Yoshida, M., Dostert, P., Naoi, M., and Nagatsu, T. (1993) Presence of tetrahydroisoquinoline-related compounds, possible MPTP-like neurotoxins, in parkinsonian brains. Adv. Neurol. 60, 234-237.
45. Melchior, C., and Collins, M. A. (1982) The route and significance of endogenous synthesis of alkaloids in animals. Crit. Rev. Toxicol. 9, 313-356.
46. Tasaki, Y., Makino, Y., Ohta, S., and Hirobe, M. (1993) Biosynthesis of 1-methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ), a possible antiparkinsonism agent. Adv. Neurol. 60, 231-233.
47. d'Ischia, M., and Prota, G. (1997) Biosynthesis, structure and function of neuromelanin and its relation to Parkinson's disease: a critical update. Pigment Cell Res. 10, 370-376.
48. Dexter, D. T., Carter, C. J., Wells, F. R., Javoy-Agid, F., Agid, Y., Lees, A., Jenner, P., and Marsden, C. D. (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 52, 382-389.
49. Nishimura, M., Umeda, M., Kusanagi, A., Urakabe, R., Yukimatsu, K., and Otawara, S. (1981) Cytomorphological study of cultured mammalian cells treated with benzaldehyde, catechol and their derivatives with special reference to inhibition of DNA synthesis. Gann 72, 272-279.